Researchers discovered potential epilepsy drugs using innovative zebrafish disease model
Epygenix Therapeutics has developed a unique drug development strategy: rapid aquarium-to-bedside drug development using repurposed drugs. The key advantages of our strategy are:
Our proprietary drug screening system with zebrafish disease model which recapitulates behavioral, electrographic, and pharmacologic characteristics of Dravet syndrome identified our drug candidates for Dravet syndrome. Human POC in patient with Dravet syndrome has been demonstrated by us and 3rd party.
Our drug candidates have been well-tolerated while on the market. Nonclinical toxicology studies as well as Phase 1 study confirmed the excellence of safety.
Superiority in both science and safety profiles speed clinical development.